Signed by Governor Kelly Armstrong

Vote Smart's Synopsis:

Vote to pass a bill that limits out-of-pocket costs for a monthly supply of insulin to $25 for the state's commercial insurance market in North Dakota.

Highlights:

• Limits out-of-pocket costs for a monthly supply of an insulin drug to $25 for the state's commercial insurance market in North Dakota (Sec. 1).

• Establishes a $25-a-month cap on insulin-related medical supplies (Sec. 1).

• Defines “insulin drug” as a prescription drug that contains insulin and is used to treat a form of diabetes mellitus, including insulin in the following categories (Sec. 1):

• Rapid-acting insulin;

• Short-acting insulin;

• Intermediate-acting insulin;

• Long-acting insulin;

• Premixed insulin product;

• Premixed insulin/GLP - 1 RA product; and

• Concentrated human regular insulin.

• Exempts the term from including an insulin pump, an electronic insulin-administering smart pen, a continuous glucose monitor, or supplies needed specifically for the use of such electronic devices (Sec. 1).

• Defines "Medical supplies for insulin dosing and administration" means supplies needed for proper insulin dosing, as well as supplies needed to detect or address medical emergencies in an individual using insulin to manage diabetes mellitus, including (Sec. 1):

• Blood glucose meters;

• Blood glucose test strips;

• Lancing devices and lancets;

• Ketone testing supplies, such as urine strips, blood ketone meters, and blood ketone strips;

• Glucagon, in injectable and nasal forms;

• Insulin pen needles; and

• Insulin syringes.

• Specifies that the provisions of this bill shall take effect immediately upon passage and approval by the Governor (Sec. 1).

Full Bill Text

Vote Smart's Synopsis:

Vote to pass a bill that limits out-of-pocket costs for a monthly supply of insulin to $25 for the state's commercial insurance market in North Dakota.

Highlights:

• Limits out-of-pocket costs for a monthly supply of an insulin drug to $25 for the state's commercial insurance market in North Dakota (Sec. 1).

• Establishes a $25-a-month cap on insulin-related medical supplies (Sec. 1).

• Defines “insulin drug” as a prescription drug that contains insulin and is used to treat a form of diabetes mellitus, including insulin in the following categories (Sec. 1):

• Rapid-acting insulin;

• Short-acting insulin;

• Intermediate-acting insulin;

• Long-acting insulin;

• Premixed insulin product;

• Premixed insulin/GLP - 1 RA product; and

• Concentrated human regular insulin.

• Exempts the term from including an insulin pump, an electronic insulin-administering smart pen, a continuous glucose monitor, or supplies needed specifically for the use of such electronic devices (Sec. 1).

• Defines "Medical supplies for insulin dosing and administration" means supplies needed for proper insulin dosing, as well as supplies needed to detect or address medical emergencies in an individual using insulin to manage diabetes mellitus, including (Sec. 1):

• Blood glucose meters;

• Blood glucose test strips;

• Lancing devices and lancets;

• Ketone testing supplies, such as urine strips, blood ketone meters, and blood ketone strips;

• Glucagon, in injectable and nasal forms;

• Insulin pen needles; and

• Insulin syringes.

• Specifies that the provisions of this bill shall take effect immediately upon passage and approval by the Governor (Sec. 1).

Full Bill Text